STRO (Sutro Biopharma, Inc.)
Insider Trading Activity
Every open-market purchase and sale reported by STRO officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-09 | Sukhi Jagpal | Director | A | — | — |
| 2026-06-09 | Michael Dybbs | Director | A | — | — |
| 2026-06-09 | CONNIE MATSUI | Director | A | — | — |
| 2026-06-09 | Daniel H Petree | Director | A | — | — |
| 2026-06-09 | JAMES P PANEK | Director | A | — | — |
| 2026-06-09 | Jon Marc Wigginton | Director | A | — | — |
| 2026-06-09 | Heidi Hunter | Director | A | — | — |
| 2026-06-09 | Joseph M Lobacki | Director | A | — | — |
| 2026-06-02 | Gregory K. Chow | CFO | M | — | — |
| 2026-03-06 | David Pauling | Chief Admin. Ofcr. & GC | MIXED | — | — |
| 2026-03-06 | Jane Chung | Chief Executive Officer | MIXED | — | — |
| 2026-03-03 | Hans-Peter Gerber | CHIEF SCIENTIFIC OFFICER | MIXED | — | — |
| 2026-03-03 | Gregory K. Chow | CFO | A | — | — |
| 2026-03-03 | David Pauling | Chief Admin. Ofcr. & GC | MIXED | — | — |
| 2026-03-03 | Jane Chung | Chief Executive Officer | MIXED | — | — |
| 2025-12-29 | Gregory K. Chow | CFO | A | — | — |
| 2025-12-29 | Daniel H Petree | Director | A | — | — |
| 2025-12-29 | Heidi Hunter | Director | A | — | — |
| 2025-12-29 | JAMES P PANEK | Director | A | — | — |
| 2025-12-29 | Hans-Peter Gerber | CHIEF SCIENTIFIC OFFICER | A | — | — |
| 2025-12-29 | Michael Dybbs | Director | A | — | — |
| 2025-12-29 | Joseph M Lobacki | Director | A | — | — |
| 2025-12-29 | Sukhi Jagpal | Director | A | — | — |
| 2025-12-29 | CONNIE MATSUI | Director | A | — | — |
| 2025-12-29 | David Pauling | Chief Admin. Ofcr. & GC | A | — | — |
| 2025-12-29 | Jon Marc Wigginton | Director | A | — | — |
| 2025-12-16 | Jane Chung | Chief Executive Officer | MIXED | — | — |
| 2025-10-16 | Gregory K. Chow | CFO | Buy | — | — |
| 2025-10-16 | CONNIE MATSUI | Director | Buy | — | — |
| 2025-10-16 | Hans-Peter Gerber | CHIEF SCIENTIFIC OFFICER | Buy | — | — |
| 2025-10-16 | David Pauling | Chief Admin. Ofcr. & GC | Buy | — | — |
| 2025-10-16 | Jane Chung | Chief Executive Officer | Buy | — | — |
| 2025-09-22 | Hans-Peter Gerber | CHIEF SCIENTIFIC OFFICER | MIXED | — | — |
| 2025-08-26 | Jane Chung | Chief Executive Officer | MIXED | — | — |
| 2025-08-26 | Barbara Leyman | Chief Business Officer | MIXED | — | — |
| 2025-06-10 | Sukhi Jagpal | Director | A | — | — |
| 2025-06-10 | Joseph M Lobacki | Director | A | — | — |
| 2025-06-10 | Daniel H Petree | Director | A | — | — |
| 2025-06-10 | JAMES P PANEK | Director | A | — | — |
| 2025-06-10 | CONNIE MATSUI | Director | A | — | — |
| 2025-06-10 | Heidi Hunter | Director | A | — | — |
| 2025-06-10 | Michael Dybbs | Director | A | — | — |
| 2025-06-10 | Jon Marc Wigginton | Director | A | — | — |
| 2025-06-02 | Gregory K. Chow | CFO | A | — | — |
| 2025-05-19 | EDWARD C ALBINI | CFO AND SECRETARY | MIXED | — | — |
| 2025-05-05 | Venkatesh Srinivasan | CHIEF TECH OP OFFICER | MIXED | — | — |
| 2025-05-05 | LINDA A FITZPATRICK | CHIEF PEOPLE & COMM. OFFICER | MIXED | — | — |
| 2025-05-05 | Anne Elizabeth Borgman | CHIEF MEDICAL OFFICER | MIXED | — | — |
| 2025-04-15 | Venkatesh Srinivasan | CHIEF TECH OP OFFICER | MIXED | — | — |
| 2025-04-08 | Venkatesh Srinivasan | CHIEF TECH OP OFFICER | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 205,684 | — |
| — | Director | 194,490 | — |
| — | 10%+ Owner | 172,620 | — |
| — | 10%+ Owner | 144,584 | — |
| — | 10%+ Owner | 143,069 | — |
| — | CEO | 40,905 | — |
| — | Chief Executive Officer | 21,285 | — |
| — | CFO AND SECRETARY | 15,652 | — |
| — | CHIEF PEOPLE & COMM. OFFICER | 13,782 | — |
| — | CHIEF MEDICAL OFFICER | 10,622 | — |
| — | Pres. Rsrch & Cf. Sctific Ofcr | 10,166 | — |
| — | Chief Admin. Ofcr. & GC | 9,748 | — |
| — | CHIEF SCIENTIFIC OFFICER | 8,308 | — |
| — | CHIEF TECH OP OFFICER | 5,369 | — |
| — | Director | 5,000 | — |
| — | CFO | 4,725 | — |
| — | Chief Technical Ops. Officer | 3,830 | — |
| — | Chief Medical Officer | 3,774 | — |
| — | Director | 2,246 | — |
| — | Chief Business Officer | 1,606 | — |
| — | Director | 1,293 | — |
| — | CHIEF PORT. STRAT & ALNCE OFCR | 1,280 | — |
| — | 10%+ Owner | 855 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the STRO quote page; the site-wide leaderboard is on the insider transactions hub.